PMID- 30542640
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 8
DP  - 2018
TI  - Human Herpesvirus 6 and Malignancy: A Review.
PG  - 512
LID - 10.3389/fonc.2018.00512 [doi]
LID - 512
AB  - In order to determine the role of human herpesvirus 6 (HHV-6) in human disease, 
      several confounding factors, including methods of detection, types of controls, 
      and the ubiquitous nature of the virus, must be considered. This is particularly 
      problematic in the case of cancer, in which rates of detection vary greatly among 
      studies. To determine what part, if any, HHV-6 plays in oncogenesis, a review of 
      the literature was performed. There is evidence that HHV-6 is present in certain 
      types of cancer; however, detection of the virus within tumor cells is 
      insufficient for assigning a direct role of HHV-6 in tumorigenesis. Findings 
      supportive of a causal role for a virus in cancer include presence of the virus 
      in a large proportion of cases, presence of the virus in most tumor cells, and 
      virus-induced in-vitro cell transformation. HHV-6, if not directly oncogenic, may 
      act as a contributory factor that indirectly enhances tumor cell growth, in some 
      cases by cooperation with other viruses. Another possibility is that HHV-6 may 
      merely be an opportunistic virus that thrives in the immunodeficient tumor 
      microenvironment. Although many studies have been carried out, it is still 
      premature to definitively implicate HHV-6 in several human cancers. In some 
      instances, evidence suggests that HHV-6 may cooperate with other viruses, 
      including EBV, HPV, and HHV-8, in the development of cancer, and HHV-6 may have a 
      role in such conditions as nodular sclerosis Hodgkin lymphoma, gastrointestinal 
      cancer, glial tumors, and oral cancers. However, further studies will be required 
      to determine the exact contributions of HHV-6 to tumorigenesis.
FAU - Eliassen, Eva
AU  - Eliassen E
AD  - HHV-6 Foundation, Santa Barbara, CA, United States.
FAU - Lum, Emily
AU  - Lum E
AD  - HHV-6 Foundation, Santa Barbara, CA, United States.
FAU - Pritchett, Joshua
AU  - Pritchett J
AD  - Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States.
FAU - Ongradi, Joseph
AU  - Ongradi J
AD  - Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary.
FAU - Krueger, Gerhard
AU  - Krueger G
AD  - Department of Pathology and Laboratory Medicine, University of Texas- Houston 
      Medical School, Houston, TX, United States.
FAU - Crawford, John R
AU  - Crawford JR
AD  - Department of Neurosciences and Pediatrics, University of California San Diego 
      and Rady Children's Hospital, San Diego, CA, United States.
FAU - Phan, Tuan L
AU  - Phan TL
AD  - HHV-6 Foundation, Santa Barbara, CA, United States.
AD  - Department of Microbiology and Immunology, Tulane University School of Medicine, 
      New Orleans, LA, United States.
FAU - Ablashi, Dharam
AU  - Ablashi D
AD  - HHV-6 Foundation, Santa Barbara, CA, United States.
FAU - Hudnall, Stanley David
AU  - Hudnall SD
AD  - Department of Pathology, Yale University, New Haven, CT, United States.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20181113
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC6277865
OTO - NOTNLM
OT  - HHV-6
OT  - HHV6
OT  - cancer
OT  - herpesvirus
OT  - human herpesvirus 6
OT  - malignant
OT  - oncogenic
OT  - transformation
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/01/01
CRDT- 2018/12/14 06:00
PHST- 2018/07/13 00:00 [received]
PHST- 2018/10/19 00:00 [accepted]
PHST- 2018/12/14 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2018.00512 [doi]
PST - epublish
SO  - Front Oncol. 2018 Nov 13;8:512. doi: 10.3389/fonc.2018.00512. eCollection 2018.